{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-033598","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.529888+00:00","generated_at":"2026-06-03T21:32:05.879261+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ABVC signs exclusive license deal with OncoX for NSCLC drug; up to $13.75M in fees + up to $12.5M royalties","bullets":["License for ABVC's single-herb botanical extract from Maitake Mushroom (BLEX 404) for NSCLC in North America for 20 years.","Aggregate license fee of $12.5M (cash or OncoX shares) due within 30 days of signing; additional $1.25M milestone after OncoX's next fundraising (no guarantee).","ABVC and affiliate Rgene also entitled to 5% royalties on net sales, capped at $12.5M, post-commercial launch.","FDA has approved IND for ABV-1519 (BLEX 404) as combination therapy with chemotherapy for NSCLC.","OncoX is a private BVI company specializing in oncology dietary supplements; deal leverages ABVC's clinical-stage pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-033598","json":"https://secwatch.observer/filing/0001213900-24-033598.json","markdown":"https://secwatch.observer/filing/0001213900-24-033598.md","text":"https://secwatch.observer/filing/0001213900-24-033598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024033598/0001213900-24-033598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024033598/ea0203971-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T21:32:05.879261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bffd55cef38207f6cbca6118da79d28f61cce1d7","claim":"ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) (effective 2024-04-16).","evidence_excerpt":"On April 16, 2024, the Company entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (\" Oncox \"), pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC's single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the “ Licensed Products ”), within North America for 20 years (the “ Oncox Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024033598/0001213900-24-033598-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"OncoX BioPharma, Inc."},{"label":"Value","value":"$6,250,000 (or 1,250,000 Oncox shares valued at $5 per share)"},{"label":"Effective","value":"2024-04-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}